INTERIM DATA FROM THE FIRST-IN-HUMAN PHASE 1/2A TRIAL OF ICM-203, AN INTRA-ARTICULAR, AAV GENE THERAPY FOR OSTEOARTHRITIS - SAFETY, TOLERABILITY, AND PRELIMINARY EVALUATION OF CLINICAL ACTIVITY IN LOW DOSE COHORT
journal contribution
posted on 2024-05-28, 05:32authored byAlison E Heald, Lucien B Solomon, Richard PageRichard Page, Yoenhee Ahn, Young Na Yum, Jayhyuk Myung, Jamie E Collins, Ali Guermazi, Dae-Won Kim
INTERIM DATA FROM THE FIRST-IN-HUMAN PHASE 1/2A TRIAL OF ICM-203, AN INTRA-ARTICULAR, AAV GENE THERAPY FOR OSTEOARTHRITIS - SAFETY, TOLERABILITY, AND PRELIMINARY EVALUATION OF CLINICAL ACTIVITY IN LOW DOSE COHORT